Science and Technology Committee examine regenerative medicine
13 October 2016
The Science and Technology Committee holds its second evidence session on regenerative medicine. This session focuses on commercialisation and transplantation stages of regenerative medicine and the challenges on clinical trials, ATMPs, regulation, market access and reimbursement and the impact on its adoption and use in the NHS.
- Watch Parliament TV: Regenerative medicine
- Inquiry: Regenerative medicine
- Science and Technology Committee
Witnesses
Wednesday 19 October 2016, 1.45 pm, Committee Room 15, Palace of Westminster
At 1.45pm
- Dr Ian Hudson, Chief Executive, Medicines and Healthcare products Regulatory Agency
- Professor Paul Whiting, Member, MRC Regenerative Medicine Research Committee
- Dr Sven Kili, Head of Gene Therapy Development, GSK
- Michael Hunt, Chief Financial Officer, ReNeuron Group
At 2.45pm
- Ian Trenholm, Chief Executive, NHS Blood and Transplant
- Ian McCubbin, Medicines Manufacturing Industry Partnership and co-chair of the Advanced Therapy Manufacturing Taskforce
- Keith Thompson, Chief Executive Officer, Cell and Gene Therapy Catapult
- Dr Ruth McKernan, Chief Executive, Innovate UK
Further information
Image: iStockphoto
Video: Parliamentary copyright